CAR T-Cell Therapy Competitive landscape report by DelveInsight 1
CAR T-Cell Therapy Competitive landscape

CAR T-Cell Therapy pipeline constitutes 193+ key companies continuously working towards developing 450+ CAR T-Cell Therapy treatment therapies, analyzes DelveInsight

A type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.

 

DelveInsights, “CAR T-Cell Therapy Competitive landscape, 2022” report provides comprehensive insights about 193+ companies and CAR T – Cell Therapy drugs in CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type,stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To know more about the CAR T-Cell Therapy pipeline analysis report, click here: CAR T-Cell Therapy Competitive landscape

 

Key Takeaways from the CAR T – Cell Therapy Competitive landscape report:

  • Leading CAR T – Cell Therapy Companies working in the market are Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, Novartis, Poseida Therapeutics, Tessa Therapeutics, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Carsgen Therapeutics, Cellular Biomedicine Group, Eureka Therapeutics, Formula Pharmaceuticals, Mustang Bio, MolMed and Others.
  • Key CAR T – Cell Therapy therapies in various stages of development include JWCAR029, JCAR017, CT 103A, MB-CART2019.1, Kymriah, KTE-X19, P-BCMA-101, Descartes-11, Orvacabtagene autoleucel, BPX-603 and Others.
  • In May 2022, Novartis announced the US Food and Drug Administration has granted accelerated approval for Kymriah (tisagenlecleucel ) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

 

DelveInsight’s CAR T – Cell Therapy Report covers around 450+ products under different phases of clinical development like

  • Assessment by CAR T – Cell Therapy Product Type
  • Assessment by Stage and Product Type of CAR T – Cell Therapy
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration of CAR T – Cell Therapy
  • Assessment by CAR T – Cell Therapy Molecule Type
  • Assessment by Stage and Molecule Type of CAR T – Cell Therapy

 

Emerging CAR T – Cell Therapy Drugs Under Different Phases of Clinical Development Include:

Some of the CAR T – Cell Therapy therapies are Kymriah, BPX-603 and Many Others.

 

Further CAR T – Cell Therapy product details are provided in the report. Download the CAR T – Cell Therapy Pipeline report to learn more about the emerging CAR T-Cell therapies at: https://www.delveinsight.com/sample-request/cart-cell-therapy-competitive-landscape

 

Key companies in the CAR T – Cell Therapy Therapeutics Market:

Some of the CAR T – Cell Therapy Companies working in the market are Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, Novartis, Poseida Therapeutics, Tessa Therapeutics, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Carsgen Therapeutics, Cellular Biomedicine Group, Eureka Therapeutics, Formula Pharmaceuticals, Mustang Bio, MolMed and Others.

 

Request for Sample PDF Report to know in detail about the recent developments  and advancements in CAR T – Cell Therapy clinical trials – Phases of CAR T – Cell Therapy Drugs in Pipeline

 

Table of Content (TOC)

1. CAR T – Cell Therapy Pipeline Report Introduction

2. CAR T – Cell Therapy Pipeline Report Executive Summary

3. CAR T – Cell Therapy Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. CAR T – Cell Therapy Clinical Trial Therapeutics

6. CAR T – Cell Therapy Pipeline: Late Stage Products (Pre-registration)

7. CAR T – Cell Therapy Pipeline: Late Stage Products (Phase III)

8. CAR T – Cell Therapy Pipeline: Mid Stage Products (Phase II)

9. CAR T – Cell Therapy Pipeline: Early Stage Products (Phase I)

10.  CAR T – Cell Therapy Pipeline Therapeutic Assessment

11. Inactive Products in the CAR T – Cell Therapy Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key CAR T – Cell Therapy Companies

14. Key Products in the CAR T – Cell Therapy Pipeline

15. Unmet Needs

16. CAR T – Cell Therapy Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

Download Sample PDF Report to know more about @ CAR T-Cell Drugs and Medication

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape

Leave a Reply

Your email address will not be published. Required fields are marked *